Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers. Stanford University researchers in the laboratory of Dr.
Researchers in Prof. Karl Deisseroth's laboratory have combined optogenetics with functional magnetic resonance imaging (fMRI) to enable highly specific in vivo analysis of brain circuits.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for cocaine-modulated behavior modification by precisely targeting defined neural circuit elements.
Researchers in Prof. Karl Deisseroth's laboratory have engineered a novel channelrhodopsin with enhanced expression, faster speed, and improved targeting.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop a precise, specific and inexpensive animal model of impaired memory.
Researchers in Prof. Karl Deisseroth's laboratory have developed a minimally invasive technique for delivering light to living tissue without optical fibers.
Researchers in Prof. Karl Deisseroth's laboratory have identified a unifying endophenotype for psychosis that could be used to develop antipsychotic treatments.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for social dysfunction by precisely targeting defined neural circuit elements.
Researchers in Prof. Karl Deisseroth's laboratory have used optogenetic tools to develop an animal model for anxiety by precisely identifying, creating, resolving, and targeting defined neural circuit elements.
Researchers in the laboratories of Dr. Karl Deisseroth and Dr. Peter Hegemann have engineered mutant ChR2 (Channelrhodopsin-2) proteins with light-sensitivity that is increased by orders of magnitude compared to wild-type ChR2.
Researchers in Prof. Karl Deisseroth's lab have discovered and engineered new microbial opsin proteins and cell trafficking tools to enable selective cell-type specific, light-sensitive switches for neuromodulation.
This invention is a practical extension of Stanford docket S05-170 (photosensitive proteins Channelrhodopsins) and describes an implantable, light-generating device for the optical stimulation of neural
The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking.
Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.
Researchers in Dr. Karl Deisseroth's laboratory have developed a novel method to rapidly identify neurophysiological measures associated with psychiatric disease and then use those correlates to screen for therapeutics.